ワクチンアジュバントの世界市場レポート 2025年

ワクチンアジュバント市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.2％で28億9,000万米ドルに成長します。予測期間の成長は、パンデミックへの備え、ワクチンポートフォリオの拡大、世界の予防接種目標、共同研究やパートナーシップ、治療用ワクチンへの注力などに起因しています。予測期間における主な動向としては、アジュバント技術の進歩、免疫原性増強への注力、有効性向上のためのアジュバント配合、より安全で忍容性の高いアジュバントへの需要、個別化ワクチンとアジュバントなどが挙げられます。

ワクチンアジュバント市場の予想成長率は、感染症の流行の増加によって牽引されると予想されます。感染症には、ウイルス、細菌、真菌、寄生虫によって引き起こされる感染症が含まれます。ワクチンは、B型肝炎（HBV）、C型肝炎（HCV）、HIV、マラリア、梅毒、ブルセラ病など、さまざまな感染症の治療に重要な役割を果たしています。2022年の世界保健機関（WHO）の報告書によると、2021年には世界で約1,060万人が結核に感染し、160万人が死亡、150万人がHIVに感染し、65万人が命を落としました。したがって、感染症の流行の高まりは、ワクチンアジュバント市場の主要な促進要因になると予想されます。

ワクチンアジュバント市場の成長は、ワクチン研究活動への資金提供の増加によっても促進されると予想されます。ワクチン研究活動は、感染症を予防するワクチンの開発、試験、強化に焦点を当てた包括的な科学的努力を包含しています。これらの調査活動は、天然物、合成化合物、さらには細菌やウイルスなど、多様な供給源に由来する潜在的なアジュバント候補の特定、試験、最適化において重要な役割を果たしています。例えば、2023年10月、米国を拠点とする重要な福祉サービスの提供者である米国保健福祉省は、次世代ワクチン接種・治療プラットフォームのための第2b相臨床試験計画と最先端技術の開発を開始するための5億米ドルの投資を含むプロジェクトNextGenを発表しました。その結果、ワクチン研究活動への資金提供の増加が、ワクチンアジュバント市場成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のワクチンアジュバント PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のワクチンアジュバント市場：成長率分析
• 世界のワクチンアジュバント市場の実績：規模と成長, 2019-2024
• 世界のワクチンアジュバント市場の予測：規模と成長, 2024-2029, 2034F
• 世界のワクチンアジュバント総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のワクチンアジュバント市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アジュバントエマルジョン
• 病原体成分
• 微粒子アジュバント
• 複合アジュバント
• その他の製品タイプ
• 世界のワクチンアジュバント市場：使用経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒトワクチンアジュバント
• 獣医ワクチンアジュバント
• 世界のワクチンアジュバント市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 筋肉内
• 鼻腔内
• 皮下
• 皮内
• 世界のワクチンアジュバント市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん
• 感染症
• その他の疾患
• 世界のワクチンアジュバント市場、タイプ別サブセグメンテーション：アジュバントエマルジョン、実績と予測, 2019-2024, 2024-2029F, 2034F
• 水中油型エマルジョン
• 油中水型エマルジョン
• 世界のワクチンアジュバント市場、タイプ別サブセグメンテーション：病原体成分、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細菌成分
• ウイルス成分
• 世界のワクチンアジュバント市場、タイプ別サブセグメンテーション：粒子状アジュバント、実績と予測, 2019-2024, 2024-2029F, 2034F
• リポソーム
• ナノ粒子
• 微粒子
• 世界のワクチンアジュバント市場、タイプ別サブセグメンテーション：複合アジュバント、実績と予測, 2019-2024, 2024-2029F, 2034F
• 混合エマルジョン
• 複数コンポーネントシステム
• 世界のワクチンアジュバント市場、タイプ別サブセグメンテーション：その他の製品タイプ、実績と予測, 2019-2024, 2024-2029F, 2034F
• 合成アジュバント
• 天然アジュバント

第7章 地域別・国別分析

• 世界のワクチンアジュバント市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のワクチンアジュバント市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ワクチンアジュバント市場：競合情勢
• ワクチンアジュバント市場：企業プロファイル
  • GlaxoSmithKline Plc. Overview, Products and Services, Strategy and Financial Analysis
  • Novavax Inc. Overview, Products and Services, Strategy and Financial Analysis
  • SPI Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Agenus Inc. Overview, Products and Services, Strategy and Financial Analysis
  • CSL Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• InvivoGen Limited
• Brenntag Biosector A/S
• Adjuvatis
• Merck KGaA
• Croda International Plc
• Seppic Inc
• OZ Biosciences
• Avanti Polar Lipids Inc
• Astellas Pharma Inc
• Virometix AG
• MPV Technologies Limited
• Adjuvance Technologies Inc.
• Novartis AG
• Vaxine Pty Ltd
• SBI Biotech Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ワクチンアジュバント市場2029：新たな機会を提供する国
• ワクチンアジュバント市場2029：新たな機会を提供するセグメント
• ワクチンアジュバント市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vaccine adjuvants refer to compounds or components included in vaccines to enhance the body's immune response to antigens that lack immunostimulatory capabilities, thereby creating a more robust immune reaction.

The primary categories of vaccine adjuvants include adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others, such as saponin-based adjuvants. Adjuvant emulsions are defined as mixtures of two or more typically immiscible liquids. These vaccine adjuvants are administered through various routes, including oral, intramuscular, intranasal, subcutaneous, and intradermal, in both human and veterinary settings. They are employed in the treatment of conditions such as cancer, infectious diseases, and other ailments, including zoonotic diseases.

The vaccine adjuvants market research report is one of a series of new reports from The Business Research Company that provides vaccine adjuvants market statistics, including the vaccine adjuvants industry's global market size, regional shares, competitors with a vaccine adjuvants market share, detailed vaccine adjuvants market segments, market trends, and opportunities, and any further data you may need to thrive in the vaccine adjuvants industry. This vaccine adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vaccine adjuvants market size has grown strongly in recent years. It will grow from$1.89 billion in 2024 to $2.03 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing vaccine development, prevalence of infectious diseases, government initiatives and immunization programs, research and development investments, globalization of vaccine distribution

The vaccine adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to pandemic preparedness, expanding vaccine portfolio, global immunization goals, collaborations and partnerships, focus on therapeutic vaccines. Major trends in the forecast period include advancements in adjuvant technologies, focus on immunogenicity enhancement, combination adjuvants for enhanced effectiveness, demand for safer and well-tolerated adjuvants, personalized vaccines and adjuvants.

The anticipated growth of the vaccine adjuvants market is expected to be driven by the increasing prevalence of infectious diseases. Infectious diseases encompass infections caused by viruses, bacteria, fungi, or parasites. Vaccines play a crucial role in treating various infectious diseases such as hepatitis B (HBV), hepatitis C (HCV), HIV, malaria, syphilis, and brucellosis. As per the 2022 World Health Organization (WHO) report, approximately 10.6 million people globally were infected with tuberculosis in 2021, resulting in 1.6 million deaths, and 1.5 million individuals contracted HIV, with 650,000 losing their lives to it. Hence, the rising prevalence of infectious diseases is expected to be a key driver for the vaccine adjuvants market.

The expected growth of the vaccine adjuvants market is also anticipated to be fueled by the increasing funding for vaccine research activities. Vaccine research activities encompass comprehensive scientific endeavors focused on developing, testing, and enhancing vaccines to prevent infectious diseases. These research activities play a crucial role in identifying, testing, and optimizing potential adjuvant candidates derived from diverse sources, including natural products, synthetic compounds, and even bacteria or viruses. For example, in October 2023, the United States Department of Health and Human Services, a US-based provider of essential human services, announced Project NextGen, involving a $500 million investment to initiate the development of Phase 2b clinical trial plans and cutting-edge technologies for next-generation vaccination and treatment platforms. Consequently, the increasing funding for vaccine research activities is a driving force behind the growth of the vaccine adjuvants market.

Product innovations are becoming a significant trend in the vaccine adjuvants market. Companies in this field are focusing on adopting innovative solutions to enhance their market positions. For example, in December 2022, Evonik Industries, a Germany-based chemical manufacturing company, launched PhytoSquene, a plant-based squalene derived from amaranth oil. This sustainable alternative to traditional shark-derived squalene is intended for use in vaccine adjuvants and other pharmaceutical applications, improving vaccine efficacy by enhancing immune responses. The introduction of PhytoSquene highlights the increasing emphasis on sustainability within the pharmaceutical industry.

Prominent companies operating in the vaccine adjuvants market are concentrating on introducing innovative products, such as plant-based squalene, to gain a competitive advantage. Plant-based squalene, derived from the herbaceous plant amaranth (Amaranthus caudatus), offers a sustainable and cruelty-free alternative to traditional squalene obtained from shark liver oil. For instance, in December 2022, Evonik Industries AG, a specialty chemicals company based in Germany, launched PhytoSquene, a plant-based squalene utilized in adjuvants to enhance vaccine efficacy. This product has applications in adjuvants for parenteral vaccines, with potential expansion into other pharmaceutical and cosmetic uses. PhytoSquene addresses the needs of patients who, due to cultural or religious beliefs, cannot use products derived from animals.

In August 2022, GSK plc, a pharmaceutical and biotechnology company based in the UK, completed the acquisition of Affinivax Inc. for a deal amount of $3.3 billion. This acquisition bolsters GSK's strategy to establish a substantial portfolio of specialized novel drugs and vaccines. It includes a next-generation 24-valent pneumococcal vaccine adjuvant (AFX3772), based on the groundbreaking Multiple Antigen Presenting System (MAPSTM) platform technology, currently in phase II development. Affinivax Inc. is a clinical-stage biopharmaceutical company based in the UK operating in the vaccine adjuvant market.

Major companies operating in the vaccine adjuvants market include GlaxoSmithKline Plc., Novavax Inc., SPI Pharma Inc., Agenus Inc., CSL Limited, InvivoGen Limited., Brenntag Biosector A/S, Adjuvatis, Merck KGaA, Croda International Plc, Seppic Inc, OZ Biosciences, Avanti Polar Lipids Inc, Astellas Pharma Inc, Virometix AG, MPV Technologies Limited, Adjuvance Technologies Inc., Novartis AG, Vaxine Pty Ltd, SBI Biotech Co. Ltd., Statens Serum Institute, GSK Vaccines, VaxLiant LLC, VaxForm LLC, Serum Institute of India, Dynavax Technologies Corporation, Vaxcyte Inc., VBI Vaccines Inc., Medicago Inc., Aphios Corporation

North America was the largest region in the vaccine adjuvants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global vaccine adjuvants market report during the forecast period. The regions covered in the vaccine adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the vaccine adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The vaccine adjuvants market consists of sales of adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and saponin-based adjuvants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vaccine Adjuvants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaccine adjuvants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaccine adjuvants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaccine adjuvants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Adjuvant Emulsions; Pathogen Components; Particulate Adjuvants; Combination Adjuvants; Other Product Types
• 2) By Route of Application: Human Vaccine Adjuvants; Veterinary Vaccine Adjuvants
• 3) By Route of Administration: Oral; Intramuscular; Intranasal; Subcutaneous; Intradermal
• 4) By Disease: Cancer; Infectious Diseases; Other Diseases
• Subsegments:
• 1) By Adjuvant Emulsions: Oil-In-Water Emulsions; Water-In-Oil Emulsions
• 2) By Pathogen Components: Bacterial Components; Viral Components
• 3) By Particulate Adjuvants: Liposomes; Nanoparticles; Microparticles
• 4) By Combination Adjuvants: Mixed Emulsions; Multiple Component Systems
• 5) By Other Product Types: Synthetic Adjuvants; Natural Adjuvants
• Companies Mentioned: GlaxoSmithKline Plc.; Novavax Inc.; SPI Pharma Inc.; Agenus Inc.; CSL Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vaccine Adjuvants Market Characteristics

3. Vaccine Adjuvants Market Trends And Strategies

4. Vaccine Adjuvants Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Vaccine Adjuvants Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vaccine Adjuvants PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vaccine Adjuvants Market Growth Rate Analysis
• 5.4. Global Vaccine Adjuvants Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vaccine Adjuvants Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vaccine Adjuvants Total Addressable Market (TAM)

6. Vaccine Adjuvants Market Segmentation

• 6.1. Global Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adjuvant Emulsions
• Pathogen Components
• Particulate Adjuvants
• Combination Adjuvants
• Other Product Types
• 6.2. Global Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Vaccine Adjuvants
• Veterinary Vaccine Adjuvants
• 6.3. Global Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intramuscular
• Intranasal
• Subcutaneous
• Intradermal
• 6.4. Global Vaccine Adjuvants Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Infectious Diseases
• Other Diseases
• 6.5. Global Vaccine Adjuvants Market, Sub-Segmentation Of Adjuvant Emulsions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oil-In-Water Emulsions
• Water-In-Oil Emulsions
• 6.6. Global Vaccine Adjuvants Market, Sub-Segmentation Of Pathogen Components, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacterial Components
• Viral Components
• 6.7. Global Vaccine Adjuvants Market, Sub-Segmentation Of Particulate Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liposomes
• Nanoparticles
• Microparticles
• 6.8. Global Vaccine Adjuvants Market, Sub-Segmentation Of Combination Adjuvants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mixed Emulsions
• Multiple Component Systems
• 6.9. Global Vaccine Adjuvants Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Synthetic Adjuvants
• Natural Adjuvants

7. Vaccine Adjuvants Market Regional And Country Analysis

• 7.1. Global Vaccine Adjuvants Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vaccine Adjuvants Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vaccine Adjuvants Market

• 8.1. Asia-Pacific Vaccine Adjuvants Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vaccine Adjuvants Market

• 9.1. China Vaccine Adjuvants Market Overview
• 9.2. China Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vaccine Adjuvants Market

• 10.1. India Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vaccine Adjuvants Market

• 11.1. Japan Vaccine Adjuvants Market Overview
• 11.2. Japan Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vaccine Adjuvants Market

• 12.1. Australia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vaccine Adjuvants Market

• 13.1. Indonesia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vaccine Adjuvants Market

• 14.1. South Korea Vaccine Adjuvants Market Overview
• 14.2. South Korea Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vaccine Adjuvants Market

• 15.1. Western Europe Vaccine Adjuvants Market Overview
• 15.2. Western Europe Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vaccine Adjuvants Market

• 16.1. UK Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vaccine Adjuvants Market

• 17.1. Germany Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vaccine Adjuvants Market

• 18.1. France Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vaccine Adjuvants Market

• 19.1. Italy Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vaccine Adjuvants Market

• 20.1. Spain Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vaccine Adjuvants Market

• 21.1. Eastern Europe Vaccine Adjuvants Market Overview
• 21.2. Eastern Europe Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vaccine Adjuvants Market

• 22.1. Russia Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vaccine Adjuvants Market

• 23.1. North America Vaccine Adjuvants Market Overview
• 23.2. North America Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vaccine Adjuvants Market

• 24.1. USA Vaccine Adjuvants Market Overview
• 24.2. USA Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vaccine Adjuvants Market

• 25.1. Canada Vaccine Adjuvants Market Overview
• 25.2. Canada Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vaccine Adjuvants Market

• 26.1. South America Vaccine Adjuvants Market Overview
• 26.2. South America Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vaccine Adjuvants Market

• 27.1. Brazil Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vaccine Adjuvants Market

• 28.1. Middle East Vaccine Adjuvants Market Overview
• 28.2. Middle East Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vaccine Adjuvants Market

• 29.1. Africa Vaccine Adjuvants Market Overview
• 29.2. Africa Vaccine Adjuvants Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vaccine Adjuvants Market, Segmentation By Route of Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vaccine Adjuvants Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vaccine Adjuvants Market Competitive Landscape And Company Profiles

• 30.1. Vaccine Adjuvants Market Competitive Landscape
• 30.2. Vaccine Adjuvants Market Company Profiles
  • 30.2.1. GlaxoSmithKline Plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novavax Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. SPI Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Agenus Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. CSL Limited Overview, Products and Services, Strategy and Financial Analysis

31. Vaccine Adjuvants Market Other Major And Innovative Companies

• 31.1. InvivoGen Limited
• 31.2. Brenntag Biosector A/S
• 31.3. Adjuvatis
• 31.4. Merck KGaA
• 31.5. Croda International Plc
• 31.6. Seppic Inc
• 31.7. OZ Biosciences
• 31.8. Avanti Polar Lipids Inc
• 31.9. Astellas Pharma Inc
• 31.10. Virometix AG
• 31.11. MPV Technologies Limited
• 31.12. Adjuvance Technologies Inc.
• 31.13. Novartis AG
• 31.14. Vaxine Pty Ltd
• 31.15. SBI Biotech Co. Ltd.

32. Global Vaccine Adjuvants Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vaccine Adjuvants Market

34. Recent Developments In The Vaccine Adjuvants Market

35. Vaccine Adjuvants Market High Potential Countries, Segments and Strategies

• 35.1 Vaccine Adjuvants Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vaccine Adjuvants Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vaccine Adjuvants Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer